Pub Date : 2022-09-24DOI: 10.33696/haematology.3.044
{"title":"Commentary on “Dynamics of Erythrocyte Deformation Properties in Wistar Rats During Postnatal Ontogeny”","authors":"","doi":"10.33696/haematology.3.044","DOIUrl":"https://doi.org/10.33696/haematology.3.044","url":null,"abstract":"","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41744882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-24DOI: 10.33696/haematology.3.045
{"title":"Postpartum Shock Following Vulvovaginal Haematoma, Rare but Keeps Coming: The Complete Case Report","authors":"","doi":"10.33696/haematology.3.045","DOIUrl":"https://doi.org/10.33696/haematology.3.045","url":null,"abstract":"","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69670064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-24DOI: 10.33696/haematology.3.041
{"title":"Commentary on” The FLAMSA Concept Past and Future”","authors":"","doi":"10.33696/haematology.3.041","DOIUrl":"https://doi.org/10.33696/haematology.3.041","url":null,"abstract":"","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47262597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-24DOI: 10.33696/haematology.3.042
{"title":"Phlebotomy in Congenital Erythrocytosis and in Sickle Cell Disease HbSC","authors":"","doi":"10.33696/haematology.3.042","DOIUrl":"https://doi.org/10.33696/haematology.3.042","url":null,"abstract":"","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44399038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-31DOI: 10.33696/haematology.2.038
Logan Hahn, Mark Bosch
The ground-breaking PARMA and CORAL trials have substantiated high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) as standard of care in the treatment of chemosensitive and relapsed Non-Hodgkin’s Lymphoma (NHL) [1,2]. Additionally, the regimen has proven effective in the treatment of relapsed and resistant Hodgkin’s Lymphoma (HL) [3,4]. Globally, carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM) has been the most widely used conditioning regimen of the past 30 years [5]. BEAM conditioning is generally well-tolerated and effective, with the most common toxicity being oral and gastrointestinal mucositis [5]. Despite this, some transplant centres have transitioned from BEAM HDCT to a newer regiment referred to as BeEAM, which replaces BCNU for bendamustine. The movement appears to be primarily driven by a worldwide scarcity of BCNU, which has led to affordability issues. This dramatic rise in drug cost is not insignificant. Between 2013 and 2015, the price of BCNU increased from $200 (CAD) / 100 mg vial to $4,965.14 (CAD) / 100 mg vial. Bendamustine was first synthesized in the former German Democratic Republic in the 1960s [6]. The mechanism of action of bendamustine is unlike that of other alkylating agents and its activity includes apoptosis, inhibition of mitotic checkpoints, and induction of mitotic catastrophe [7]. A phase I-II trial conducted by Visani et al. found bendamustine to be safe and efficacious in the transplant setting, reporting a 100-day transplant-related mortality of 0%. Additionally, 81% of the 77-patient cohort was in complete remission at a median observation of 18 months [6].
{"title":"BeEAM Conditioning for Autologous Transplant in Lymphoma: A Review of the Evidence, Safety and Efficacy","authors":"Logan Hahn, Mark Bosch","doi":"10.33696/haematology.2.038","DOIUrl":"https://doi.org/10.33696/haematology.2.038","url":null,"abstract":"The ground-breaking PARMA and CORAL trials have substantiated high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) as standard of care in the treatment of chemosensitive and relapsed Non-Hodgkin’s Lymphoma (NHL) [1,2]. Additionally, the regimen has proven effective in the treatment of relapsed and resistant Hodgkin’s Lymphoma (HL) [3,4]. Globally, carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM) has been the most widely used conditioning regimen of the past 30 years [5]. BEAM conditioning is generally well-tolerated and effective, with the most common toxicity being oral and gastrointestinal mucositis [5]. Despite this, some transplant centres have transitioned from BEAM HDCT to a newer regiment referred to as BeEAM, which replaces BCNU for bendamustine. The movement appears to be primarily driven by a worldwide scarcity of BCNU, which has led to affordability issues. This dramatic rise in drug cost is not insignificant. Between 2013 and 2015, the price of BCNU increased from $200 (CAD) / 100 mg vial to $4,965.14 (CAD) / 100 mg vial. Bendamustine was first synthesized in the former German Democratic Republic in the 1960s [6]. The mechanism of action of bendamustine is unlike that of other alkylating agents and its activity includes apoptosis, inhibition of mitotic checkpoints, and induction of mitotic catastrophe [7]. A phase I-II trial conducted by Visani et al. found bendamustine to be safe and efficacious in the transplant setting, reporting a 100-day transplant-related mortality of 0%. Additionally, 81% of the 77-patient cohort was in complete remission at a median observation of 18 months [6].","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46056061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-31DOI: 10.33696/haematology.2.039
Weiwei Wang, G. Fan, Lisong Shen
With the development of immune therapy, the role of immune monitoring during treatments has been emphasized. Flow cytometry is the best method for immune status monitoring because of its characteristic of multi-parameter analysis. To broadly monitor immune status, we established and validated a multi-color comprehensive panel of 29 antibodies to cover 90 immune cell subsets and the research work was published in the issue of ILSH recently [1]. The article reported that the clinical applications of 10-color flow cytometry to monitor the immune status of patients before or after clinical treatments in 2 ml whole blood samples.
{"title":"Deep Immune Status Monitoring with Multi-color Flow Cytometry","authors":"Weiwei Wang, G. Fan, Lisong Shen","doi":"10.33696/haematology.2.039","DOIUrl":"https://doi.org/10.33696/haematology.2.039","url":null,"abstract":"With the development of immune therapy, the role of immune monitoring during treatments has been emphasized. Flow cytometry is the best method for immune status monitoring because of its characteristic of multi-parameter analysis. To broadly monitor immune status, we established and validated a multi-color comprehensive panel of 29 antibodies to cover 90 immune cell subsets and the research work was published in the issue of ILSH recently [1]. The article reported that the clinical applications of 10-color flow cytometry to monitor the immune status of patients before or after clinical treatments in 2 ml whole blood samples.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42437950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-31DOI: 10.33696/haematology.2.037
A. M. Haidary, Haider Ali Malakzai, A. Khairy, Sayed Ali Hashimi, Ramin Saadaat, Mujtaba Haidari, J. Abdul-Ghafar, Abdul Jamil Rasooli, Sarah, Noor, S. Noor, Maryam Ahmad, Ahmad Shekib Zahier, Samuel Sharif, A. Sami, Ibrahimkhil, Esmatullah Esmat
Ahmed Maseh Haidary1*, Haider Ali Malakzai1, Abdul Latif Khairy1, Sayed Ali Hashimi1, Ramin Saadaat1, Mujtaba Haidari1, Jamshid Abdul-Ghafar1, Abdul Jamil Rasooli2, Sarah Noor3, Sahar Noor2, Maryam Ahmad1, Ahmad Shekib Zahier4, Samuel Sharif1, Abdul Sami Ibrahimkhil1, Esmatullah Esmat1 1Department of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children, Kabul, Afghanistan 2Department of Paediatric medicine, French Medical Institute for Mothers and Children, Kabul, Afghanistan 3Department of Haemato-Oncology, Jumhoriat Hosptial, Kabul, Afghanistan 4Department of Haemato-Oncology, Amiri Medical Complex, Kabul, Afghanistan *Correspondence should be addressed to Ahmed Maseh Haidary; ahmedmaseh.haidary@fmic.org.af
Ahmed Maseh Haidary1*、Haider Ali Malakzai1、Abdul Latif Khairy1、Sayed Ali Hashimi1、Ramin Saadaat1、Mujtaba Haidari1、Jamshid Abdul- ghafar1、Abdul Jamil Rasooli2、Sarah Noor3、Sahar Noor2、Maryam Ahmad1、Ahmad Shekib Zahier4、Samuel Sharif1、Abdul Sami Ibrahimkhil1、Esmatullah Esmat1、阿富汗喀布尔法国母亲和儿童医学研究所病理和临床实验室2、法国母亲和儿童医学研究所儿科医学部1、阿富汗喀布尔3阿富汗喀布尔Jumhoriat医院血液肿瘤科4阿富汗喀布尔Amiri综合医院血液肿瘤科*信件应寄给Ahmed Maseh Haidary;ahmedmaseh.haidary@fmic.org.af
{"title":"Acute Myeloid Leukaemia with inv (16) in a 2-year-old Boy: A Diagnostic Dilemma","authors":"A. M. Haidary, Haider Ali Malakzai, A. Khairy, Sayed Ali Hashimi, Ramin Saadaat, Mujtaba Haidari, J. Abdul-Ghafar, Abdul Jamil Rasooli, Sarah, Noor, S. Noor, Maryam Ahmad, Ahmad Shekib Zahier, Samuel Sharif, A. Sami, Ibrahimkhil, Esmatullah Esmat","doi":"10.33696/haematology.2.037","DOIUrl":"https://doi.org/10.33696/haematology.2.037","url":null,"abstract":"Ahmed Maseh Haidary1*, Haider Ali Malakzai1, Abdul Latif Khairy1, Sayed Ali Hashimi1, Ramin Saadaat1, Mujtaba Haidari1, Jamshid Abdul-Ghafar1, Abdul Jamil Rasooli2, Sarah Noor3, Sahar Noor2, Maryam Ahmad1, Ahmad Shekib Zahier4, Samuel Sharif1, Abdul Sami Ibrahimkhil1, Esmatullah Esmat1 1Department of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children, Kabul, Afghanistan 2Department of Paediatric medicine, French Medical Institute for Mothers and Children, Kabul, Afghanistan 3Department of Haemato-Oncology, Jumhoriat Hosptial, Kabul, Afghanistan 4Department of Haemato-Oncology, Amiri Medical Complex, Kabul, Afghanistan *Correspondence should be addressed to Ahmed Maseh Haidary; ahmedmaseh.haidary@fmic.org.af","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43331343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-31DOI: 10.33696/haematology.2.040
K. Togo, A. Yamashita
In hemodialysis therapy for end-stage kidney disease (ESKD) patients, blood and dialysate are brought into contact through the dialysis membrane to remove waste products and excess water. When blood contacts the dialysis membrane, blood cells, coagulation system, fibrinolysis system, kallikrein system, and complement system are activated. Therefore, dialysis membranes with excellent blood compatibility must be chosen to avoid such reactions to occur. In this article, we review blood compatibilities of each dialysis membrane material.
{"title":"Blood Compatibility in Various Hemodialysis Membrane Materials: A Review","authors":"K. Togo, A. Yamashita","doi":"10.33696/haematology.2.040","DOIUrl":"https://doi.org/10.33696/haematology.2.040","url":null,"abstract":"In hemodialysis therapy for end-stage kidney disease (ESKD) patients, blood and dialysate are brought into contact through the dialysis membrane to remove waste products and excess water. When blood contacts the dialysis membrane, blood cells, coagulation system, fibrinolysis system, kallikrein system, and complement system are activated. Therefore, dialysis membranes with excellent blood compatibility must be chosen to avoid such reactions to occur. In this article, we review blood compatibilities of each dialysis membrane material.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44685818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-10DOI: 10.33696/haematology.2.032
Lan Gao, M. Weetall, K. O’Keefe, Elizabeth Goodwin, Ronald Kong
A hallmark of all cancers is the rapid rates of cell division associated with tumor growth. Rapid cell division is dependent upon the assembly and disassembly of microtubules, which are essential components of the mitotic spindle and are critical for the movement and separation of chromosomes during cell division [1]. Microtubules are dynamic filaments that are composed of αβ-tubulin heterodimers. Microtubules also play key roles in determining cell shape, cell motility, and transportation of organelles within the cell. Blocking normal microtubular function leads to a failure of cells to progress through cell division and ultimately results in cell death.
{"title":"Unesbulin – a Novel Anti-tubulin Cancer Therapeutic","authors":"Lan Gao, M. Weetall, K. O’Keefe, Elizabeth Goodwin, Ronald Kong","doi":"10.33696/haematology.2.032","DOIUrl":"https://doi.org/10.33696/haematology.2.032","url":null,"abstract":"A hallmark of all cancers is the rapid rates of cell division associated with tumor growth. Rapid cell division is dependent upon the assembly and disassembly of microtubules, which are essential components of the mitotic spindle and are critical for the movement and separation of chromosomes during cell division [1]. Microtubules are dynamic filaments that are composed of αβ-tubulin heterodimers. Microtubules also play key roles in determining cell shape, cell motility, and transportation of organelles within the cell. Blocking normal microtubular function leads to a failure of cells to progress through cell division and ultimately results in cell death.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43354576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：